Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2023 1
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Unique pharmacodynamic properties and low abuse liability of the µ-opioid receptor ligand (S)-methadone.
Levinstein MR, De Oliveira PA, Casajuana-Martin N, Quiroz C, Budinich RC, Rais R, Rea W, Ventriglia EN, Llopart N, Casadó-Anguera V, Moreno E, Walther D, Glatfelter GC, Weinshenker D, Zarate CA Jr, Casadó V, Baumann MH, Pardo L, Ferré S, Michaelides M. Levinstein MR, et al. Mol Psychiatry. 2024 Mar;29(3):624-632. doi: 10.1038/s41380-023-02353-z. Epub 2023 Dec 25. Mol Psychiatry. 2024. PMID: 38145984 Free PMC article.
The CB1 receptor interacts with cereblon and drives cereblon deficiency-associated memory shortfalls.
Costas-Insua C, Hermoso-López A, Moreno E, Montero-Fernández C, Álvaro-Blázquez A, Maroto IB, Sánchez-Ruiz A, Diez-Alarcia R, Blázquez C, Morales P, Canela EI, Casadó V, Urigüen L, Perea G, Bellocchio L, Rodríguez-Crespo I, Guzmán M. Costas-Insua C, et al. EMBO Mol Med. 2024 Apr;16(4):755-783. doi: 10.1038/s44321-024-00054-w. Epub 2024 Mar 21. EMBO Mol Med. 2024. PMID: 38514794 Free PMC article.
Reply to "Letter to the Editor regarding 'Unique pharmacodynamic properties and low abuse liability of the μ-opioid receptor ligand (S)-methadone'".
Levinstein MR, De Oliveira PA, Casajuana-Martin N, Quiroz C, Budinich RC, Rais R, Rea W, Ventriglia EN, Llopart N, Casadó-Anguera V, Moreno E, Walther D, Glatfelter GC, Weinshenker D, Zarate CA Jr, Casadó V, Baumann MH, Pardo L, Ferré S, Michaelides M. Levinstein MR, et al. Mol Psychiatry. 2024 Dec 6. doi: 10.1038/s41380-024-02864-3. Online ahead of print. Mol Psychiatry. 2024. PMID: 39639176 No abstract available.